Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers Sells 6,983 Shares

Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $77.30, for a total value of $539,785.90. Following the completion of the sale, the executive vice president now directly owns 42,908 shares of the company’s stock, valued at approximately $3,316,788.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Wendy Carruthers also recently made the following trade(s):

• On Monday, June 3rd, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The shares were sold at an average price of $75.33, for a total value of $526,029.39.

Boston Scientific Stock Up 0.1 %

Shares of BSX stock traded up $0.10 on Tuesday, hitting $76.51. The stock had a trading volume of 2,202,871 shares, compared to its average volume of 6,265,786. The firm has a market capitalization of $112.25 billion, a price-to-earnings ratio of 64.18, a P/E/G ratio of 2.65 and a beta of 0.78. The stock’s 50 day moving average is $75.01 and its 200-day moving average is $67.81. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $77.99.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.05. The business had revenue of $3.86 billion during the quarter, compared to the consensus estimate of $3.68 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. As a group, research analysts expect that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its stake in Boston Scientific by 29.7% during the 2nd quarter. GAMMA Investing LLC now owns 12,460 shares of the medical equipment provider’s stock valued at $960,000 after acquiring an additional 2,854 shares during the last quarter. Transcend Capital Advisors LLC boosted its stake in Boston Scientific by 2.2% during the 2nd quarter. Transcend Capital Advisors LLC now owns 6,773 shares of the medical equipment provider’s stock valued at $522,000 after acquiring an additional 148 shares during the last quarter. Bank of New Hampshire bought a new position in Boston Scientific during the 2nd quarter valued at $113,000. Cypress Asset Management Inc. TX bought a new position in Boston Scientific during the 1st quarter valued at $205,000. Finally, Railway Pension Investments Ltd boosted its stake in Boston Scientific by 73.0% during the 1st quarter. Railway Pension Investments Ltd now owns 367,600 shares of the medical equipment provider’s stock valued at $25,177,000 after acquiring an additional 155,100 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. UBS Group raised their price target on Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Barclays raised their price target on shares of Boston Scientific from $70.00 to $78.00 and gave the stock an “overweight” rating in a research note on Friday, April 26th. Argus raised their price target on Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, May 28th. Mizuho upped their price target on shares of Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Finally, JPMorgan Chase & Co. upped their price target on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $77.41.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.